Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion
panels are appropriately comprised of experts who are free of conflicts of interest "Guidelines should have a consistent and transparent method of development, be of uniformly high quality, and
While regular physical activity offers many health benefits and can increase the number of calories you burn, it is possible to lose weight through dietary changes alone
The appropriateness of semaglutide, including dose and duration, must be determined through a medical evaluation
& Horrocks, L
In this episode of the Huberman Lab podcast, Victor Carrin examines the nature of post-traumatic stress disorder (PTSD), especially in children and adolescents whose developing brains are susceptible to lasting impacts